The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment

Findings from PROTECT

John R. Teerlink, Vicente J. Iragui, Jay P. Mohr, Peter E. Carson, Paul Hauptman, David H. Lovett, Alan B. Miller, Ileana L. Piña, Scott Thomson, Paul D. Varosy, Michael R. Zile, John G.F. Cleland, Michael M. Givertz, Marco Metra, Piotr Ponikowski, Adriaan A. Voors, Beth A. Davison, Gad Cotter, Denise Wolko, Paul DeLucca & 5 others Christina M. Salerno, George A. Mansoor, Howard Dittrich, Christopher M. O'Connor, Barry M. Massie

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes. Objective: The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A1-receptor antagonist, in patients with acute heart failure. Methods: The effect of rolofylline was investigated in patients hospitalized for acute heart failure with impaired renal function. Intravenous rolofylline 30mg or placebo was infused over 4 hours daily for up to 3 days. Adverse events (AEs) and serious AEs (SAEs) were recorded from baseline through 7 and 14 days, respectively, and clinical events were adjudicated through 60 days. Results: Of 2033 patients enrolled, 2002 received study drug randomized 2 : 1 to rolofylline or placebo. Rolofylline and placebo were associated with a similar risk of pre-specified groups of AEs or SAEs, other than selected neurological events. Investigator-reported seizures occurred in 11 (0.8%) rolofylline-treated patients and zero patients receiving placebo (p = 0.02). Stroke occurred in 21 (1.6%) patients assigned to rolofylline compared with 3 (0.5%) placebo-treated patients through 60 days with a greater risk for stroke in the rolofylline group (hazard ratio 3.49; 95%CI 1.04, 11.71; p = 0.043). There was no temporal relation to rolofylline administration and no specific stroke subtype or clinical characteristics that predicted stroke in the rolofylline group. Conclusions: Rolofylline treatment was associated with an increased seizure rate, an anticipated complication of A1-receptor antagonists. An unanticipated, disproportionate increase in strokes in the rolofylline-treated patients emerged, although no clear temporal relation, aetiology, stroke subtype or interacting factor suggestive of a causal mechanism was identified. Further research into stroke as a potential complication of adenosine-modulating therapies is required. Additionally, this study underscores the value of longer follow-up durations for AEs, even for agents with short treatment periods, such as in acute heart failure. Trial Registration: ClinicalTrials.gov identifiers NCT00328692 and NCT00354458.

Original languageEnglish (US)
Pages (from-to)233-244
Number of pages12
JournalDrug Safety
Volume35
Issue number3
DOIs
StatePublished - Feb 23 2012

Fingerprint

Adenosine A1 Receptor Antagonists
Acute Kidney Injury
Heart Failure
Safety
Stroke
Placebos
Adenosine
rolofylline
Seizures
Purinergic P1 Receptors
Therapeutics

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment : Findings from PROTECT. / Teerlink, John R.; Iragui, Vicente J.; Mohr, Jay P.; Carson, Peter E.; Hauptman, Paul; Lovett, David H.; Miller, Alan B.; Piña, Ileana L.; Thomson, Scott; Varosy, Paul D.; Zile, Michael R.; Cleland, John G.F.; Givertz, Michael M.; Metra, Marco; Ponikowski, Piotr; Voors, Adriaan A.; Davison, Beth A.; Cotter, Gad; Wolko, Denise; DeLucca, Paul; Salerno, Christina M.; Mansoor, George A.; Dittrich, Howard; O'Connor, Christopher M.; Massie, Barry M.

In: Drug Safety, Vol. 35, No. 3, 23.02.2012, p. 233-244.

Research output: Contribution to journalArticle

Teerlink, JR, Iragui, VJ, Mohr, JP, Carson, PE, Hauptman, P, Lovett, DH, Miller, AB, Piña, IL, Thomson, S, Varosy, PD, Zile, MR, Cleland, JGF, Givertz, MM, Metra, M, Ponikowski, P, Voors, AA, Davison, BA, Cotter, G, Wolko, D, DeLucca, P, Salerno, CM, Mansoor, GA, Dittrich, H, O'Connor, CM & Massie, BM 2012, 'The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: Findings from PROTECT', Drug Safety, vol. 35, no. 3, pp. 233-244. https://doi.org/10.2165/11594680-000000000-00000
Teerlink, John R. ; Iragui, Vicente J. ; Mohr, Jay P. ; Carson, Peter E. ; Hauptman, Paul ; Lovett, David H. ; Miller, Alan B. ; Piña, Ileana L. ; Thomson, Scott ; Varosy, Paul D. ; Zile, Michael R. ; Cleland, John G.F. ; Givertz, Michael M. ; Metra, Marco ; Ponikowski, Piotr ; Voors, Adriaan A. ; Davison, Beth A. ; Cotter, Gad ; Wolko, Denise ; DeLucca, Paul ; Salerno, Christina M. ; Mansoor, George A. ; Dittrich, Howard ; O'Connor, Christopher M. ; Massie, Barry M. / The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment : Findings from PROTECT. In: Drug Safety. 2012 ; Vol. 35, No. 3. pp. 233-244.
@article{ea0f23a42fe94cfcb13ee029558bdf03,
title = "The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: Findings from PROTECT",
abstract = "Background: Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes. Objective: The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A1-receptor antagonist, in patients with acute heart failure. Methods: The effect of rolofylline was investigated in patients hospitalized for acute heart failure with impaired renal function. Intravenous rolofylline 30mg or placebo was infused over 4 hours daily for up to 3 days. Adverse events (AEs) and serious AEs (SAEs) were recorded from baseline through 7 and 14 days, respectively, and clinical events were adjudicated through 60 days. Results: Of 2033 patients enrolled, 2002 received study drug randomized 2 : 1 to rolofylline or placebo. Rolofylline and placebo were associated with a similar risk of pre-specified groups of AEs or SAEs, other than selected neurological events. Investigator-reported seizures occurred in 11 (0.8{\%}) rolofylline-treated patients and zero patients receiving placebo (p = 0.02). Stroke occurred in 21 (1.6{\%}) patients assigned to rolofylline compared with 3 (0.5{\%}) placebo-treated patients through 60 days with a greater risk for stroke in the rolofylline group (hazard ratio 3.49; 95{\%}CI 1.04, 11.71; p = 0.043). There was no temporal relation to rolofylline administration and no specific stroke subtype or clinical characteristics that predicted stroke in the rolofylline group. Conclusions: Rolofylline treatment was associated with an increased seizure rate, an anticipated complication of A1-receptor antagonists. An unanticipated, disproportionate increase in strokes in the rolofylline-treated patients emerged, although no clear temporal relation, aetiology, stroke subtype or interacting factor suggestive of a causal mechanism was identified. Further research into stroke as a potential complication of adenosine-modulating therapies is required. Additionally, this study underscores the value of longer follow-up durations for AEs, even for agents with short treatment periods, such as in acute heart failure. Trial Registration: ClinicalTrials.gov identifiers NCT00328692 and NCT00354458.",
author = "Teerlink, {John R.} and Iragui, {Vicente J.} and Mohr, {Jay P.} and Carson, {Peter E.} and Paul Hauptman and Lovett, {David H.} and Miller, {Alan B.} and Pi{\~n}a, {Ileana L.} and Scott Thomson and Varosy, {Paul D.} and Zile, {Michael R.} and Cleland, {John G.F.} and Givertz, {Michael M.} and Marco Metra and Piotr Ponikowski and Voors, {Adriaan A.} and Davison, {Beth A.} and Gad Cotter and Denise Wolko and Paul DeLucca and Salerno, {Christina M.} and Mansoor, {George A.} and Howard Dittrich and O'Connor, {Christopher M.} and Massie, {Barry M.}",
year = "2012",
month = "2",
day = "23",
doi = "10.2165/11594680-000000000-00000",
language = "English (US)",
volume = "35",
pages = "233--244",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment

T2 - Findings from PROTECT

AU - Teerlink, John R.

AU - Iragui, Vicente J.

AU - Mohr, Jay P.

AU - Carson, Peter E.

AU - Hauptman, Paul

AU - Lovett, David H.

AU - Miller, Alan B.

AU - Piña, Ileana L.

AU - Thomson, Scott

AU - Varosy, Paul D.

AU - Zile, Michael R.

AU - Cleland, John G.F.

AU - Givertz, Michael M.

AU - Metra, Marco

AU - Ponikowski, Piotr

AU - Voors, Adriaan A.

AU - Davison, Beth A.

AU - Cotter, Gad

AU - Wolko, Denise

AU - DeLucca, Paul

AU - Salerno, Christina M.

AU - Mansoor, George A.

AU - Dittrich, Howard

AU - O'Connor, Christopher M.

AU - Massie, Barry M.

PY - 2012/2/23

Y1 - 2012/2/23

N2 - Background: Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes. Objective: The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A1-receptor antagonist, in patients with acute heart failure. Methods: The effect of rolofylline was investigated in patients hospitalized for acute heart failure with impaired renal function. Intravenous rolofylline 30mg or placebo was infused over 4 hours daily for up to 3 days. Adverse events (AEs) and serious AEs (SAEs) were recorded from baseline through 7 and 14 days, respectively, and clinical events were adjudicated through 60 days. Results: Of 2033 patients enrolled, 2002 received study drug randomized 2 : 1 to rolofylline or placebo. Rolofylline and placebo were associated with a similar risk of pre-specified groups of AEs or SAEs, other than selected neurological events. Investigator-reported seizures occurred in 11 (0.8%) rolofylline-treated patients and zero patients receiving placebo (p = 0.02). Stroke occurred in 21 (1.6%) patients assigned to rolofylline compared with 3 (0.5%) placebo-treated patients through 60 days with a greater risk for stroke in the rolofylline group (hazard ratio 3.49; 95%CI 1.04, 11.71; p = 0.043). There was no temporal relation to rolofylline administration and no specific stroke subtype or clinical characteristics that predicted stroke in the rolofylline group. Conclusions: Rolofylline treatment was associated with an increased seizure rate, an anticipated complication of A1-receptor antagonists. An unanticipated, disproportionate increase in strokes in the rolofylline-treated patients emerged, although no clear temporal relation, aetiology, stroke subtype or interacting factor suggestive of a causal mechanism was identified. Further research into stroke as a potential complication of adenosine-modulating therapies is required. Additionally, this study underscores the value of longer follow-up durations for AEs, even for agents with short treatment periods, such as in acute heart failure. Trial Registration: ClinicalTrials.gov identifiers NCT00328692 and NCT00354458.

AB - Background: Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes. Objective: The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A1-receptor antagonist, in patients with acute heart failure. Methods: The effect of rolofylline was investigated in patients hospitalized for acute heart failure with impaired renal function. Intravenous rolofylline 30mg or placebo was infused over 4 hours daily for up to 3 days. Adverse events (AEs) and serious AEs (SAEs) were recorded from baseline through 7 and 14 days, respectively, and clinical events were adjudicated through 60 days. Results: Of 2033 patients enrolled, 2002 received study drug randomized 2 : 1 to rolofylline or placebo. Rolofylline and placebo were associated with a similar risk of pre-specified groups of AEs or SAEs, other than selected neurological events. Investigator-reported seizures occurred in 11 (0.8%) rolofylline-treated patients and zero patients receiving placebo (p = 0.02). Stroke occurred in 21 (1.6%) patients assigned to rolofylline compared with 3 (0.5%) placebo-treated patients through 60 days with a greater risk for stroke in the rolofylline group (hazard ratio 3.49; 95%CI 1.04, 11.71; p = 0.043). There was no temporal relation to rolofylline administration and no specific stroke subtype or clinical characteristics that predicted stroke in the rolofylline group. Conclusions: Rolofylline treatment was associated with an increased seizure rate, an anticipated complication of A1-receptor antagonists. An unanticipated, disproportionate increase in strokes in the rolofylline-treated patients emerged, although no clear temporal relation, aetiology, stroke subtype or interacting factor suggestive of a causal mechanism was identified. Further research into stroke as a potential complication of adenosine-modulating therapies is required. Additionally, this study underscores the value of longer follow-up durations for AEs, even for agents with short treatment periods, such as in acute heart failure. Trial Registration: ClinicalTrials.gov identifiers NCT00328692 and NCT00354458.

UR - http://www.scopus.com/inward/record.url?scp=84857176387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857176387&partnerID=8YFLogxK

U2 - 10.2165/11594680-000000000-00000

DO - 10.2165/11594680-000000000-00000

M3 - Article

VL - 35

SP - 233

EP - 244

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 3

ER -